Cellular current controversies in pharmaceutical costs in the US and the free market competition solution

Abstract

Pharmaceutical prices in the United States, both proprietary brand names and generics have skyrocketed over the last two decades. The prices of generics, although there are multiple worldwide manufacturers, have gone up exponentially. One of the significant costs drivers in the United States are the PBM,’s pharmacy benefits managers, middlemen. Author presentation will document this and a solution to the problem will be presented. He will show that the repeal of the PBM Safeharbor granted by the federal government in two, has resulted in major price increases. If the safe harbor is removed, prices will plummet to a stable point.He will show that the repeal of the PBM Safeharbor granted by the US federal government in 2002, has resulted in major price increases. If the PBM Safe-harbor is removed, prices will plummet to a stable point as determined by market forces.